Paris Saclay, France , May 13, 2023 - RegenLab, a global bio-medical technology company specializing in the research, development, manufacturing and marketing of proprietary tissue engineering products has been nominated “Innovation Champion award” by the EIB – European Investment Bank at the (EIB) ADVenture Debt Summit taking place on the 13th of May 2024 at the European Convention Center in Luxembourg.
This award is the outcome of the debt contract committed between RegenLab and the EIB back in October 2021.
The loan was dedicated to launch a factory of the RegenLab products in Paris Saclay and to finance the specific clinical studies for RegenMatrix PRP-HA, a new generation of tube combining PRP (platelet rich plasma) and cross linked Hyaluronic Acid for grade 3-4 knee osteoarthritis.
“ We are honored and delighted to receive such a reward from the European Investment Bank, a recognition for the successful completion of our french factory and R&D efforts. The objective is to innovate in biotechnology to improve the well-being of patients” said Mr Antoine Turzi CEO of RegenLab France.
The Paris Saclay factory is launching its production line with the two flagship products RegenKit PRP and Cellular Matrix PRP-HA, Tissue Engineering.
The RegenMatrix PRP-HA clinical study is advancing steadily with 108 patients included in over 16 Hospital and University hospitals across the french territory.
About RegenLab
Based in Paris Saclay, les Ulis, RegenLab France is a global commercial-stage medical technology company specialized in the research, development, registration, manufacturing and commercialization of proprietary tissue engineering solutions. The Company’s solutions are commercialized in more than 90 countries. The core technology of the Company focuses on the design of solutions for autologous platelet-rich plasma (PRP) based procedures, consisting in reinjecting the patient’s own cells and platelets into tissue lesions in order to stimulate tissue healing. The Company’s original medical devices, commercialized primarily under the RegenKit brand, have been CE marked EU-MDR 2017/745 and approved by US-FDA and CFDA and are routinely used by physicians worldwide for the treatment of a wide variety of indications currently including joint osteoarthritis, tendinopathies and dermo-esthetics. The Company’s products are also manufactured in the factory of Le Mont-sur-Lausanne (Switzerland), New York (USA) since Q3 2022 and Les Ulis (Paris Saclay, France) starting Q3 2023, which the Company has built to meet its anticipated increasing demand for its new products.
Contacts:
RegenLab | Antoine Turzi | C.E.O.
RegenLab France | Jean-Marc Biscarrat | Chief Financial Officer